ScripHatteras Venture Partners marked its 25th year of investing in seed- and early-stage biopharmaceutical, medical device and health technology companies by announcing that it closed two new funds with $
ScripA look forward at the potential 2030 company rankings by prescription (Rx) and over-the-counter (OTC) sales, according to Evaluate consensus forecasts, reveals a competitive landscape being reshaped
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Sandoz, Lupin In Lucentis Biosimil
ScripQ2 Earnings Picture Darkens Big pharma earnings season started off well, but things changed towards the end of the second week, when Sanofi announced its financial results. Sanofi’s report triggered s